InMode (NASDAQ:INMD) Rating Lowered to "Neutral" at Robert W. Baird

InMode (NASDAQ:INMD - Get Free Report) was downgraded by research analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating in a research note issued to investors on Monday,Briefing.com Automated Import reports. They presently have a $16.00 price target on the healthcare company's stock, down from their previous price target of $22.00. Robert W. Baird's price target would indicate a potential upside of 13.81% from the company's current price.

A number of other research analysts have also weighed in on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of InMode in a research note on Monday. Jefferies Financial Group lowered their target price on shares of InMode from $16.00 to $15.00 and set a "hold" rating on the stock in a report on Monday, April 14th. Finally, Barclays raised their price objective on InMode from $26.00 to $29.00 and gave the company an "overweight" rating in a research report on Wednesday, February 5th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, InMode presently has an average rating of "Hold" and a consensus price target of $20.20.

InMode Price Performance

Shares of InMode stock traded down $2.16 during trading on Monday, hitting $14.06. 3,395,060 shares of the company were exchanged, compared to its average volume of 1,241,886. The firm has a market capitalization of $977.93 million, a P/E ratio of 5.96 and a beta of 1.96. The firm's fifty day moving average price is $17.36 and its 200 day moving average price is $17.65. InMode has a 1-year low of $13.68 and a 1-year high of $19.85.

Institutional Trading of InMode

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Marathon Asset Management Ltd raised its stake in InMode by 2.7% during the first quarter. Marathon Asset Management Ltd now owns 187,259 shares of the healthcare company's stock worth $3,322,000 after buying an additional 4,910 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in InMode during the first quarter worth $192,000. Bessemer Group Inc. bought a new position in InMode during the first quarter valued at about $617,000. Kirr Marbach & Co. LLC IN increased its stake in shares of InMode by 9.4% during the 1st quarter. Kirr Marbach & Co. LLC IN now owns 88,625 shares of the healthcare company's stock worth $1,572,000 after purchasing an additional 7,601 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. bought a new stake in shares of InMode in the first quarter valued at $204,000. 68.04% of the stock is currently owned by institutional investors and hedge funds.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.